By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Research findings on Oncology are discussed in a new report. According to news reporting originating from Poznan, Poland, by NewsRx correspondents, research stated, "Development of modern proteomic methods in recent years has opened also new perspectives in the identification of new biomarkers which ensure more effective diagnosis, treatment monitoring and prediction of therapeutic outcome. We evaluated usefulness of comparative proteomics (MALDI-TOF) in two subtypes of acute myeloid leukemia (AML), M1 and M2, according to FAB classification."
Our news editors obtained a quote from the research from Institute for Computer Science, "The bone marrow or blood cell proteomes were examined in 33 newly diagnosed patients before '3 + 7' induction therapy, after treatment and when the disease relapsed. We found that bone marrow and peripheral mononuclear cells from healthy volunteers revealed a number of quantitative and qualitative differences between the two proteomes, reflecting differences in the maturational status of normal cells. Such differences were not detected in our AMLM1/M2 patients. Additionally, we found 9 proteins, which are potential biomarkers differentiating between the AML patients and healthy volunteers. Using comparative proteomics, we found that annexin I, glutathione transferase omega, esterase D and gamma 1 actin had prognostic significance. Applying statistical methods, we detected two proteins which might allow to predict results of induction therapy in AMLM1/M2. One of them was esterase D, the higher concentration of which was associated with higher complete remission rate, and the other was gamma 1 actin, the higher concentration of which was related to resistance."
According to the news editors, the research concluded: "In the article, we also discussed the role of these two proteins in the biology of AML, and we suggested potential usefulness of modification in induction therapy reflecting the presence of proteins."
For more information on this research see: Esterase D and gamma 1 actin level might predict results of induction therapy in patients with acute myeloid leukemia without and with maturation. Medical Oncology, 2013;30(4):296-304. Medical Oncology can be contacted at: Humana Press Inc, 999 Riverview Drive Suite 208, Totowa, NJ 07512, USA. (Springer - www.springer.com; Medical Oncology - www.springerlink.com/content/1357-0560/)
The news editors report that additional information may be obtained by contacting M. Kazmierczak, Poznan Univ Technical, Inst Comp Sci, PL-60965 Poznan, Poland. Additional authors for this research include M. Luczak, K. Lewandowski, L. Handschuh, A. Czyz, M. Jarmuz, M. Gniot, M. Michalak, M. Figlerowicz and M. Komarnicki (see also Oncology).
Keywords for this news article include: Poznan, Poland, Europe, Oncology, Peptides, Proteins, Esterases, Treatment, Hematology, Hydrolases, Amino Acids, Enzymes and Coenzymes, Leukemia Gene Therapy, Acute Myeloid Leukemia
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC